Evidence supporting the use of: EGCG
For the health condition: Arteriosclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin gallate (EGCG), a major polyphenol in green tea, has been investigated for its potential cardiovascular benefits, including its role in the management of arteriosclerosis (atherosclerosis). Preclinical studies (in vitro and animal models) have shown that EGCG can exert antioxidant, anti-inflammatory, and anti-proliferative effects on vascular cells. Specifically, EGCG has been found to inhibit low-density lipoprotein (LDL) oxidation and reduce the expression of adhesion molecules and inflammatory cytokines involved in the development of arterial plaques.

Some small-scale human studies and epidemiological data associate higher green tea consumption with reduced cardiovascular risk, but direct clinical evidence that isolated EGCG supplementation prevents or treats arteriosclerosis in humans is limited. Most human trials focus on cardiovascular risk factors (such as cholesterol, blood pressure, or endothelial function) rather than direct measures of arteriosclerosis progression or regression. Systematic reviews have concluded that while EGCG is promising and biologically plausible as a supportive agent, the current evidence is insufficient to recommend its use as a primary or adjunct treatment for arteriosclerosis in clinical practice.

In summary, EGCG is supported by promising preclinical data and some supportive epidemiological evidence, but there is a lack of high-quality, direct clinical trials validating its efficacy specifically for arteriosclerosis. The evidence is thus rated moderate to low (2/5) and further research is needed.

More about EGCG
More about Arteriosclerosis

Products containing EGCG

We currently have no products on Vitabase that contain this ingredient.